PREDICTORS OF SURVIVAL IN DISSEMINATED PROSTATE CANCER PATIENTS RECEIVING HORMONAL THERAPY
https://doi.org/10.17650/1726-9776-2011-7-2-78-83
Abstract
Background and objective. The division of patients with disseminated prostate cancer (PC) into prognostic groups may be potentially used for a differential approach to choosing the hormonal therapy (HT) option and regimen. This study was conducted to identify factors influencing survival, as well as prognostic groups in this category of patients.
Subjects. The study enrolled 113 patients with verified cT2b–4N0–1M0–1 stage PC. Their median age was 70.0 ± 7.3 years. The median pretreatment prostate-specific antigen (PSA) concentration was 309.8 ng/ml. The stage cT2 was diagnosed in 12 (10.6 %) patients; cT3 was in 85 (75.2 %); cT4 in 16 (14.2 %); cN+ in 32 (28.3 %); М+ in 74 (65.5 %). The median baseline Gleason score was 3.0± 0.8 ± 4.0± 0.9 =7.0± 1.6. All the patients received emergency HT: castration was carried out in 2 (1.8 %) patients; maximum androgenic block and antiandrogen monotherapy were performed in 96 (85.0 %) and 15 (13.3 %), patients, respectively. The median follow-up was 31.9± 17.7 months.
Results. Five-year progression-free, hormone-refractory prostate cancer-free, specific, and overall survivals (OS) were 29.7, 31.8, 39.3, and 26.0 %, respectively. Multivariate analysis has shown that OS is negatively influenced by the following factors: bone pain, stages cT4, М+, a nadir of PSA of 4 ng/ml (p < 0.05) and its baseline level of 100 ng/ml (р = 0.057). Good (no bone pain, a PSA level of < 100 ng/ml, сТ < T4, and М0) and poor (bone pain and/or a PSA level of 100 ng/ml, and/or stages cT4 and/or М+) prognostic groups were identified. The median OS in the groups was 39.8± 3.9 and 29.8± 4.2 months, respectively (р = 0.048).
Conclusion. In disseminated PC, bone pain, a PSA level of 100 ng/ml, cT4 and M+, and a PSA nadir of 4 ng/ml are poor predictors of OS. The patients without these indicators belong to a good prognostic group; those have one sign or more do to a poor prognostic one.
About the Authors
E. R. Babaev
Cancer Dispensary Four, South Administrative District, Moscow
Russian Federation
Russian Federation
V. B. Matveev
Department of Urology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
M. I. Volkova
Department of Urology, N.N. Blokhin Russian Cancer Research Center, Russian Academy of Medical Sciences, Moscow
Russian Federation
Russian Federation
References
1. Давыдов М.И., Аксель Е.М. Статистика злокачественных новообразований в России и странах СНГ в 2007 году. М., 2009; с. 57.
2. Матвеев Б.П., Бухаркин Б.В., Матвеев В.Б. Рак предстательной железы. М., 1999.
3. Heidenreich A., Aus G., Bolla M. et al. EAU guidelines on prostate cancer. Eur Urol 2008;53:68–80.
4. Citrin D.L., Resnick M.I., Guinan P. et al. A comparison of Zoladex results of a randomised, multicenter trial. Prostate 1991;18(2):139–46.
5. The Leuprolide Study Group. N Engl J Med 1984;311(20):1281–6.
6. Denis L., Murphy G.P. Overview of phase III trials on combined androgenic treatment in patients treated with metastatic prostate cancer. Cancer 1993;72(Suppl 12):3888–95.
7. Halabi Susan, Nicholas J. Vogelzang, Alice B. Kornblith et al. Small pain predicts overall survival in men with metastatic castrationrefractory prostate cancer. J Clin Oncol 2008; 26(15):2544–9.
8. Schröder F.H. Management of locally advanced prostate cancer. Staging, natural history, and results of radical surgery. World J Urol 2000;18(3):194–203.
9. Matzkin H., Perito P.E., Soloway M.S. Prognostic factors in metastatic prostate cancer. Cancer 1993;72(12 Suppl):3788–92.
10. Matzkin H., Soloway M.S., Schellhammer P.F. et al. Prognostic factors in stage D2 prostate cancer treated with a pure nonsteroidal antiandrogen. Cancer 1993;72(4):1286–90.
11. Nayyar R., Sharma N., Gupta N.P. Prognostic factors affecting progression and survival in metastatic prostate cancer. Urol Int 2010;84(2):159–63.
12. Cooperberg M.R., Hinotsu S., Namiki M. et al. Risk assessment among prostate cancer patients receiving primary androgen deprivation therapy. J Clin Oncol 2009;27(26):4306–13.
13. Humphrey P.A. Gleason grading and prognostic factors in carcinoma of the prostate. Mod Pathol 2004;17(3):292–306.
14. Shurbaji M.S., Kalbfleisch J.H., Thurmond T.S. Immunohistochemical detection of p53 protein as a prognostic indicator in prostate cancer. Hum Pathol 1995;26:106–9.
15. Dominique S., Ravery V. Preoperative imaging studies: is there any necessity? EAU Update Series 2005;3:72–6.
16. Soloway M.S. The importance of prognostic factors in advanced prostate cancer.Cancer 1990;66(5 Suppl):1017–21.
17. Hussain M., Tangen C.M., Higano C. et al. Southwest Oncology Group Trial 9346 (INT-0162). Absolute prostate-specific antigen value after androgen deprivation is a strong independent predictor of survival in new metastatic prostate cancer: data from Southwest Oncology Group Trial 9346 (INT-0162). J Clin Oncol 2006;24(24):3984–90.
18. Akaza H., Hinotsu S., Usami M. et al. Combined androgen blockade with bicalutamide for advanced prostate cancer. Long-Term Follow-Up of a Phase 3, DoubleBlind, Randomized Study for Survival. Cancer 2009;115:3437–45.
19. Hori S., Jabbar T., Kachroo N. et al. Outcomes and predictive factors for biochemical relapse following primary androgen deprivation therapy in men with bone scan negative prostate cancer. J Cancer Res Clin Oncol 2010. [Epub ahead of print].
Review
For citations:
Babaev E.R., Matveev V.B., Volkova M.I. PREDICTORS OF SURVIVAL IN DISSEMINATED PROSTATE CANCER PATIENTS RECEIVING HORMONAL THERAPY. Cancer Urology. 2011;7(2):78-83. (In Russ.) https://doi.org/10.17650/1726-9776-2011-7-2-78-83
Views:
1282
Email this article 